Insulin-like growth factor-I in the therapy of non-insulin-dependent diabetes mellitus and insulin resistance;IGF-1 et therapeutique du diabete non-insulino-dependant et de l'insulinoresistance

Diabetes and Metabolism

Volumn 22, Issue 4, 1996, Pages 261-267

  Froesch, E R ^a   Bianda, T ^b   Hussain, M A ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b NONE

Author keywords

growth hormone; insulin resistance; insulin sensitivity; insulin like growth factor I; Type 2 diabetes mellitus

Indexed keywords

RECOMBINANT SOMATOMEDIN C;

CLINICAL TRIAL; DRUG EFFICACY; DRUG OVERDOSE; DRUG SCREENING; HORMONAL THERAPY; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

DIABETES MELLITUS, TYPE 2; GROWTH HORMONE; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; LIPOPROTEINS; RECOMBINANT PROTEINS; SECRETORY RATE;

EID: 0030015606     PISSN: 03381684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Baxter R. Circulating binding proteins of insulin-like growth factors. Trends Endocrinol Metab, 1993, 4, 91-96.
2. Guler HP, Zapf J, Froesch ER. Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med, 1987, 317, 137-140.
3. Schoenle E, Zapf J, Humbel RE, Froesch ER. Insulin-like growth factor 1 stimulates growth in hypophysectomized rats. Nature Lond, 1982, 323, 169-171.
4. Guler H-P, Zapf J, Scheiwiller E, Froesch ER. Recombinant human insulin-like growth factor I stimulates growth and has distinct effects on organ size in hypophysectomized rats. Proc Natl Acad Sci USA, 1988, 85, 4889-4893.
5. Van-Buul-Offers S, Ueda I, Van den Brande JL. Biosynthetic somatomedin C (SM-C/IGF-I) increases the length and weight of Snell dwarf mice. Pediatr Res, 1986, 20, 825-827.
6. Laron Z, Anin S, Klipper-Aurbach Y, Klinger B. Effects of insulin-like growth factor on linear growth, head circumference, and body fat in patients with Laron-type dwarfism. Lancet, 1992, 339, 1258-1261.
7. Scheiwiller E, Guler H-P, Merryweather J et al. Growth restoration of insulin-deficient diabetic rats by recombinant human insulin-like growth factor I. Nature, 1986, 323, 169-171.
8. Guler HP, Schmid C, Zapf J, Froesch ER. Effects of recombinant insulin-like growth factor I on insulin secretion and renal function in normal human subjects. Proc Natl Acad Sci USA, 1989, 86, 22868-2872.
9. Zenobi PD, Graf S, Ursprung H, Froesch ER. Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion. J Clin Invest, 1992, 89, 1908-1913.
10. Hussain MA, Schmitz O, Mengel A et al. Insulin-like growth factor I stimulates lipid oxidation, reduces protein oxidation, and enhances insulin sensitivity in man. J Clin Invest, 1993, 92, 2249-2256.
11. Hussain MA, Schmitz O, Mengel A et al. Comparison of the effectsof growth hormone and insulin-like growth factor I on substrate oxidation and on insulin sensitivity in growth hormone-deficient humans. J Clin Inest, 1994, 94, 1126-1133.
12. Boulware SD, Tamborlane WV, Matthews LS, Sherwin RS. Diverse effects of insulin-like growth factor I on glucose, lipid, and amino acids. Am J Physiol, 1992, 262, E130-133.
13. Laager R, Ninnis R, Keller U. Comparison of the effects of rhIGF-I and insulin on glucose and leucine kinetics in man. J Clin Invest, 1993, 92, 1903-1909.
14. Froesch ER, Guler H-P, Schmid Ch, Binz K, Zapf J. Therapeutic potential of insulinlike growth factor 1. Trends in Endocrinology, New York: Elsevier Science Publishing Co Inc. 1990, 1, 254-260.
15. Zenobi PD, Jaeggi-Groisman SE, Riesen W, Roder M, Foresch ER. Insulin-like growth factor-1 improves glucose and lipid metabolism in type 2 diabetes mellitus. J Clin Invest, 1992, 90, 2234-2241.
16. Zenobi PD, Holzmann P, Glatz Y, Riesen WF, Froesch ER. Improvement of lipid profile in type 2 (non-insulin-dependent) diabetes mellitus by insulin-like growth factor I. Diabetologia, 1993, 36, 465-469.
17. Oscarsson J, Lundstam U, Gustafsson B, Wilton P, Edén S, Wiklund O. Recombinant human insulin-like growth factor-I decreases serum lipoprotein(a) concentrations in normal adult men. Clin Endocrinol, 1995, 42, 673-676.
18. Kades WW, Elsewafay SA, Ayad MF et al. Low-doses of insulin-like growth factor-I (IGF-I) improve insulin sensitivity (abstract 381). Diabetes, 1994, 43 (suppl 1).
19. Bianda T, Hussain MA, Keller A et al. Insulin-like growth factor-I in man enhances lipid mobilization and oxidation induced by a growth hormone pulse Diabetologia, in press.
20. Cheetham TD, Jones J, Taylor AM, Holly J, Matthews DR, Dunger DB. The effects of recombinant insulin-like growth factor I administration on growth hormone levels and insulin requirements in adolescents with type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1993, 36, 678-681.
21. Dunger DB. IGF-I treatment of type I diabetic subjects. Presented at the annual meeting of the European Society of Clinical Investigation, Toledo, Spain, April 20-23, 1994.
22. Schoenle EJ, Zenobi PD, Toressani T, Werder EA, Zachmann M, Froesch ER. Recombinant human insulin-like growth factor I (rhIGF-I) reduces hyperglycemia in patients with extreme insulin resistance. Diabetologia, 1991, 34, 675-679.
23. Zenobi PD, Glatz Y, Keller A et al. Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol 1994, 131, 251-257.
24. Kuzuya H, Masuura N, Sakamoto M et al. Trial of insulin-like growth factor I therapy in patients with extreme insulin resistance syndromes. Diabetes, 1993, 42, 696-705.
25. Hone J, Skarulis MC, Roach P et al. IGF I treatment of severely insulin-resistant child with short stature and diabetes mellitus (abstract 1319). Presented at the 76th Annual Endocrine Society Meeting, 1993.
26. Hussain et al., in press.